Etaracizumab

Etaracizumab: Clinical Potential and Developmental Insights[edit]

Etaracizumab, also known as etaratuzumab and marketed under the trade name Abegrin, is a humanized monoclonal antibody that has become a focus of interest in oncology^[1]. Produced by MedImmune, this agent embodies a novel approach in the realm of targeted cancer therapies. The development and trajectory of etaracizumab provide a glimpse into the sophisticated realm of antibody engineering and the demanding transition of potential anticancer agents from laboratories to clinical use.

Chemical and Biological Properties[edit]

Etaracizumab distinguishes itself through its unique binding affinity and specificity. As with all monoclonal antibodies, it is devised to identify and attach itself to a specific antigen, in this instance, an epitope predominantly displayed on certain tumor cells^[2].

Clinical Indications[edit]

Research into etaracizumab has spanned across various cancer types, such as:

Metastatic melanoma: A virulent skin cancer variant known for its metastatic prowess.
Prostate cancer: A prevalent male malignancy.
Ovarian cancer: A gynecologic cancer notorious for its late diagnosis.
Amongst other cancer types

Etaracizumab's potential indications span a wide array of malignancies, demonstrating its versatility as a therapeutic agent^[3].

Developmental Journey: From Vitaxin to Etaracizumab[edit]

The trajectory of etaracizumab reflects an era of meticulous drug enhancement. It builds upon its predecessor, Vitaxin (or MEDI-523). The lineage of both etaracizumab and Vitaxin traces back to the mouse-derived antibody LM609.

Transitioning from LM609 to Vitaxin and subsequently to etaracizumab underscores the iterative enhancements aimed at increasing therapeutic outcomes, minimizing potential immunogenic responses, and refining drug properties. Such advancements are pivotal in biologics, where subtle structural or sequence alterations can critically impact its efficacy and therapeutic scope^[4].

Manufacturing and Commercial Considerations[edit]

Synthesizing, purifying, and mass-producing monoclonal antibodies like etaracizumab come with inherent challenges. MedImmune shoulders the responsibility of maintaining the uniformity, safety, and potency of etaracizumab throughout its production. Biologics, given their intricate nature, necessitate especially rigorous manufacturing protocols^[5].

Conclusion[edit]

Etaracizumab's evolution, from its origins in the mouse antibody LM609 and subsequent refinement from Vitaxin, underscores the intricate and rewarding process of oncological drug development. As investigations persist and a richer dataset emerges, the potential role of etaracizumab in cancer treatment will further crystallize, promising new horizons for patients globally.

References[edit]

↑ Ridgway, J.B., et al. (1999). Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clinical & Experimental Metastasis, 17(6), 507-514.
↑ Brooks, P.C., et al. (1994). Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79(7), 1157-1164.
↑ Dechantsreiter, M.A., et al. (1999). N-Methylated cyclic RGD peptides as highly active and selective αVβ3 integrin antagonists. Journal of medicinal chemistry, 42(16), 3033-3040.
↑ Goodman, S.L., & Picard, M. (2012). Integrins as therapeutic targets. Trends in pharmacological sciences, 33(7), 405-412.
↑ Kozlowski, S., et al. (2012). Developing the nation's biosimilars program. New England Journal of Medicine, 367(8), 705-707.

This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page.

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] Ridgway, J.B., et al. (1999). Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clinical & Experimental Metastasis, 17(6), 507-514.

[2] Brooks, P.C., et al. (1994). Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79(7), 1157-1164.

[3] Dechantsreiter, M.A., et al. (1999). N-Methylated cyclic RGD peptides as highly active and selective αVβ3 integrin antagonists. Journal of medicinal chemistry, 42(16), 3033-3040.

[4] Goodman, S.L., & Picard, M. (2012). Integrins as therapeutic targets. Trends in pharmacological sciences, 33(7), 405-412.

[5] Kozlowski, S., et al. (2012). Developing the nation's biosimilars program. New England Journal of Medicine, 367(8), 705-707.

[1]

[2]

[3]

[4]

[5]